Drug intelligence / Profile preview

Tesio kinase inhibitor

Development stage: Preclinical
Lead developer: Tesio Pharmaceuticals
Modality: Small Molecules

Overview

Tesio Pharmaceuticals is developing a next-generation anti-inflammatory therapeutic platform centered on small molecule kinase inhibition. The company's lead program targets a central molecular checkpoint that governs the activation of a broad array of inflammatory genes. By inhibiting this specific kinase, the therapy aims to provide a more comprehensive resolution of inflammation compared to agents targeting single cytokines. Currently in the preclinical stage, the program is being evaluated for the treatment of chronic inflammatory and fibrotic conditions, specifically lung fibrosis (including idiopathic pulmonary fibrosis) and osteoarthritis.

Other names: Tesio anti-inflammatory kinase inhibitorTesio lead program

Beyond the preview

Go deeper on Tesio kinase inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tesio kinase inhibitor.

Explore the full profile